Alembic obtains FDA nod for 2 genericsDesipramine hydrochloride tablets had a market value of roughly $7 million, while erlotinib tablets had a market value of $37 million, for the 12 months ended March 2021, according to IQVIA. Alembic gets FDA blessing for generic MacrodantinNitrofurantoin capsules have a market value of roughly $23 million for the 12 months ended March 2021, according to IQVIA. FDA tentatively OKs new dosage strength of Zydus’ generic Gilenya Zydus Cadilla had previously received the agency's approval to market the generic in a 0.5 mg dosage strength. Aurobindo Pharma continues injectable business restructuring Aurobindo is consolidating all of its injectable business and related assets under its subsidiary Eugia Pharma. Camber intros generic Klor-Con Camber's potassium chloride extended-release tablets are used to prevent or treat low blood levels of potassium (hypokalemia). Breckenridge signs multiproduct agreement with Welding The agreement currently covers one delayed-release tablet product and two injectable products, which collectively had sales of $300 million for the year ended April 2021. AAM reflects on anniversary of USMCA In celebrating USMCA's one-year anniversary, the AAM said the trade deal has been a win for companies, health systems, patients and taxpayers. Amneal launches 1st generic of Intelence Intelence had a U.S. market size of roughly $99.4 million for the year ended April 2021, according to IQVIA data. FDA clears Cipla’s generic Brovana Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA. Lupin debuts generic Truvada Emtricitabine and tenofovir disoproxil fumarate tablets had a market value of $2.1 billion, according to March 2021 IQVIA data. First Previous 112 113 114 115 116 Next Last
